Tango Therapeutics, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 76/100
What the filing says
On August 11, 2026, Tango Therapeutics registered a prospectus supplement for up to $400 million in common stock (par value $0.001) via an at-the-market (ATM) sales agreement with an unnamed sales agent. The offering is covered by a Form S-3ASR filed November 21, 2025. No shares have been issued yet; this establishes authorization and legal validity subject to future board approval and pricing.
Why this rating
ATM offering of $400M equals 75.7% of company's $528M market cap—material dilution risk. However, neutral impact because this is financing capacity, not executed dilution; near-term execution unknown.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.